SAVER: Spontaneous Atrio Ventricular Conduction Preservation

Sponsor
LivaNova (Industry)
Overall Status
Completed
CT.gov ID
NCT00655213
Collaborator
(none)
622
67
4
37
9.3
0.3

Study Details

Study Description

Brief Summary

In case of sinus node dysfunction, it is often necessary to choose the safer option provided by a DDD pacemaker even though the most appropriate mode of pacing is AAI mode.

In addition to saving energy, the latter mode allows spontaneous ventricular activation, the haemodynamic consequences of which are, in most cases, better than those obtained with dual chamber pacing.

Recent studies as the MOST study suggest also that ventricular desynchronization imposed by right ventricular apical pacing even when AV synchrony is preserved increases the risk of atrial fibrillation in patients with SND. Similar results were already given by anterior studies (PIPAF) which, taking into account the percentage of ventricular pacing, suggested that AF prevention algorithm in combination with a preserved native conduction are efficient in reducing AF burden.

However, current practice is to implant a dual chamber pacemaker to prevent the risk of atrioventricular block (AVB) even if DDDR pacing with a fixed long AV delay was found inefficient in reducing ventricular pacing and was associated with a high risk of arrhythmias.

The Symphony 2550 cardiac pacemaker offers pacing modes that automatically switch from AAI(R) mode to DDD(R) or DDI(R) in event of severe atrioventricular conduction disorder, irrespective of whether or not these are accompanied by an atrial arrhythmia, returning spontaneously to AAI(R) mode as soon as the spontaneous AV conduction has resumed. These 2 particular modes are called the AAI SafeR and DDD/AMC (R) mode.

The main differences between both modes are that (i) AAI SafeR does not trigger any AV Delay after a sensed or paced atrial event which allows long PR intervals or even limited ventricular pauses with no switch to DDD(R), while (ii) DDD/AMC (R) is able to optimize AV Delay after switching to DDD(R) according to measured spontaneous conduction times and to provide an acceleration in case of vaso-vagal syndrome. This pacing mode has previously been assessed in clinical studies.

This study intends to demonstrate that the automatic modes switching significantly reduce the percentage of ventricular pacing in patients implanted with a spontaneous AV conduction and reduce the occurrence of atrial arrhythmias, on a mid-term follow-up period, in comparison to standard DDD pacing with long AVDelay.

Condition or Disease Intervention/Treatment Phase
  • Device: Symphony D 2450
  • Device: Symphony DR 2550
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
622 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Spontaneous Atrio Ventricular Conduction Preservation
Study Start Date :
Nov 1, 2003
Actual Primary Completion Date :
Dec 1, 2006
Actual Study Completion Date :
Dec 1, 2006

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 1

AAISafeR mode programming

Device: Symphony D 2450

Device: Symphony DR 2550

Active Comparator: 2

DDD with long AV Delay programming

Device: Symphony D 2450

Device: Symphony DR 2550

Active Comparator: 3

DDDAMC mode programming

Device: Symphony D 2450

Device: Symphony DR 2550

Other: 4

AAISafer mode programming in non randomized patients

Device: Symphony D 2450

Device: Symphony DR 2550

Outcome Measures

Primary Outcome Measures

  1. mean percentage of ventricular pacing between the randomized branches on a two-months period (M3 visit) [2 months]

  2. mean percentage of ventricular pacing between the studied groups during the whole study (up to 1 year). [12 months]

Secondary Outcome Measures

  1. percentage of ventricular pacing two month after randomization versus the percentage reported at the end of the first month follow-up in AAIsafeR mode. [12 months]

  2. AF burden relatively to the branch of the protocol [12 months]

  3. evolution of conduction disturbances by documentings nature, number and duration of ario-ventricular blocks. [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient has been primo-implanted with a Symphony™ 2550 or 2450 devices for less than 3 months

  • Patient with a normal spontaneous AV conduction at rest (PR < 250 ms)

  • Patient implanted for Sinus Node Dysfunction, Braycardia-Tachycardia Syndrome, carotid sinus syndrome/ vaso vagal syndrome or paroxistic AV Block

  • Patient implanted with a bipolar right-atrial lead and ventricular lead available in the local market

  • Patient has signed a consent form after having received the appropriate information

Exclusion Criteria:
  • Permanent 1st, 2nd or 3rd AV block

  • Patient having a medical status complying with one of the following cases

  • patient suffering from sustained ventricular arrhythmias

  • patient having sustained a myocardial infarction within the last month

  • patient having undergone cardiac surgery within the last month

  • patient suffering from severe aortic stenosis

  • patient suffering from unstable angina pectoris

  • patient presents with permanent atrial arrhythmias

  • Patient is not able to understand the study objectives and protocol or refuses to co-operate

  • Patient is not available for scheduled follow-up

  • Patient has a life expectancy less than one year

  • Patient is included into another clinical study

  • Patient is minor or a pregnant woman

Contacts and Locations

Locations

Site City State Country Postal Code
1 Onze lieve Vrouw ziekenhuis Aalst Belgium
2 Clinique Louis Caty Baudour Belgium
3 Hôpital universitaire Brugmann Bruxelles Belgium
4 Europa ziekenhuis Campus st. Elisabeth Uccle Belgium
5 Heiling Hart van Jezus Moen Belgium
6 Hôpital Vésale (univ.) Montigny Le Tilleul Belgium
7 CHU - Tivoli Tivoli Belgium
8 Centre Hospitalier Aix-en-Provence France
9 CH Albi Albi France
10 CHU d'Angers Angers France
11 CHU Jean Minjoz Besancon France
12 CH de CASTRES Castres-mazamet France
13 Hospice St-Jacques-Hôspital G.Montpied Clermont-Ferrand France
14 CHU - Hopital Michallon Grenoble France 38043
15 CHRU de Lille - Hôpital Cardiologique Lille France
16 CHU de Limoges Limoges France
17 CH Montpellier Montpellier France
18 CH Emile Muller Mulhouse France
19 CHU de Nantes Nantes France
20 Nouvelles Cliniques Nantaises Nantes France
21 CHU de Nice Nice France
22 Clinique Bizet Paris cedex 16 France 75116
23 CHU Pontchaillou Rennes France
24 CHU Hopital C. Nicolle Rouen France 76035
25 InParys Cardiology St Cloud France
26 CHU de Nancy Vandoeuvre les Nancy France 54511
27 Marien Hospital Bonn Germany
28 Universitätskliniken Bonn Bonn Germany
29 St.Josef-Stift Bremen Bremen Germany
30 St. Salvator Krankenhaus Halberstadt Halberstadt Germany
31 Holzminden Praxis Bub Holzminden Germany
32 Hürth Sana Hürth Germany
33 Herzzentrum Kassel Kassel Germany
34 KH Holweide Koln Germany
35 Klinikum Lüdenscheid Luedenscheid Germany
36 Universitätsklinikum Schleswig-Holstein Lübeck Germany
37 Städt. Kh. Lüneburg Lüneburg Germany
38 Univ. Mainz Mainz Germany
39 Univ. Marburg Marburg Germany
40 Klinkum Memmingen Memmingen Germany
41 Augustinum Munchen Germany
42 Klinikum Bogenhausen Munchen Germany
43 Rot-Kreuz Krankenhaus Munchen Germany
44 Praxis Bitar Peine Germany
45 Uni Regensburg Regensburg Germany
46 Prof. Frey Praxis Starnberg Starnberg Germany
47 Uni Ulm Ulm Germany
48 Waren-Müritzklinikum Waren Germany
49 Klinikum Wolgast Wolgast Germany
50 Ospedale Moscati Avellino Italy
51 Ospedale Mellini Chiari (BS) Italy
52 Ospedale Civile Conegliano (TV) Italy
53 Ospedale S. G. Battista Foligno (PG) Italy
54 Ospedale Umberto I Mestre (VE) Italy
55 Ospedale Civile Portogruaro (VE) Italy
56 Istituto Policlinico San Donato Italy
57 Ospedale Civile Sesto S. Giovanni (MI) Italy
58 Ospedale Civile Trento Italy
59 Ospedale Civili Reuniti Venezia Italy
60 Ospedale Civile Voghera Italy
61 Queen Elizabeth Hospital Birmingham United Kingdom
62 Bristol Royal Infirmary Bristol United Kingdom
63 Queens Hospital Burton on Trent United Kingdom
64 Castle Hill Hospital Hull United Kingdom
65 Leeds General Infirmary Leeds United Kingdom
66 Barts and The London NHS Trust London United Kingdom
67 St Thomas' Hospital, London United Kingdom

Sponsors and Collaborators

  • LivaNova

Investigators

  • Principal Investigator: Jean Marc DAVY, PhD, CH Montpellier

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00655213
Other Study ID Numbers:
  • IGXD02 - SAVER
First Posted:
Apr 9, 2008
Last Update Posted:
Apr 9, 2008
Last Verified:
Apr 1, 2008

Study Results

No Results Posted as of Apr 9, 2008